ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR107

A Central Role of the Enzyme Asparagine Synthetase (ASNS) in Driving Glutamine Anaeplerosis in the Metabolic Rewiring of ADPKD

Session Information

Category: Genetic Diseases of the Kidney

  • 1001 Genetic Diseases of the Kidney: Cystic

Authors

  • Podrini, Christine, San Raffaele Scientific Institute, Milan, Italy
  • Rowe, Isaline, San Raffaele Scientific Institute, Milan, Italy
  • Pagliarini, Roberto, San Raffaele Scientific Institute, Milan, Italy
  • Henriques da Costa, Ana Sofia, MRC Cancer Unit, University of Cambridge, Cambridge, United Kingdom
  • Chiaravalli, Marco, San Raffaele Scientific Institute, Milan, Italy
  • Kim, Hyunho, Center for Medical Innovation, Seoul National University Hospital, Seoul, Korea (the Republic of)
  • Qian, Feng, University of Maryland School of Medicine, Baltimore, Maryland, United States
  • Frezza, Christian, MRC Cancer Unit, University of Cambridge, Cambridge, United Kingdom
  • Boletta, Alessandra, San Raffaele Scientific Institute, Milan, Italy
Background

We showed that the Warburg effect is a feature of PKD. However, additional pathways involved in the metabolic deregulation of ADPKD are likely present. Here, we explore global metabolomics and isotope tracing experiments to identify new targetable metabolic pathways in PKD.

Methods

16 newborn (P4) kidneys of Ksp-Cre;Pkd1flox/− mice and their respective littermate controls were collected. Metabolomics was performed with LC-mass spectrometry (MS). Tracing studies with13C-labeled carbons from glucose or glutamine were performed in Pkd1-mutant cells, using LC-MS.

Results

Metabolomics screen identified 488 significantly altered metabolites. PCA and HCA showed a clear separation between cystic and control samples. The alterations included glycolysis, fatty acid oxidation and biosynthesis, and massive TCA cycle. To test which energy source was fuelling the accumulation of TCA cycle metabolites, alternate labelling with [13C6] glucose or [13C5,15N2] glutamine was performed in-vitro. Pkd1-/- cells had an enhanced glucose uptake, mostly used to produce lactate and minimally funneled into the TCA cycle. To compensate, Pkd1-/- cells uptake more glutamine and use it both oxidatively and reductively in the TCA cycle to drive fatty acids biosynthesis. Following the fate of the 15N2-glutamine, we found a significant increase of 15N-labelled asparagine in Pkd1-/- cells suggesting that they exhibit increase asparagine synthesis from glutamine. This reaction is catalyzed by Asparagine synthetase (ASNS). Indeed, Asns was upregulated in Pkd1-/- cells and KspCre;Pkd1 kidneys. Tracing with 15N2 and 13C5-glutamine showed that silencing of Asns reduced significantly the levels of labelled asparagine and glutamine-derived α-KG. Importantly, the down-regulation of Asns reduced growth in Pkd1-/- cells, but not in controls. Combination with glucose starvation was lethal in Pkd1-/- cells. Microarray analysis on Pkd1 mutant kidneys (Pkd1V/V) and human PKD1 samples confirmed upregulation of ASNS and further validated the global metabolic perturbations observed.

Conclusion

Our data show that increased glutaminolysis, interlinked with asparagine metabolism is an important feature of PKD and targeting ASNS might offer a novel therapeutic opportunity.